^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | erlotinib (EGFR inhibitor) + Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase Ib/II Trial of BRAF and EGFR inhibition in BRAFV600E metastatic colorectal cancer and other cancers: EVICT (Erlotinib and Vemurafenib In Combination Trial)
Published date:
01/13/2023
Excerpt:
We conducted a phase Ib/II dose-escalation/expansion trial investigating the safety/efficacy of the BRAF inhibitor vemurafenib and EGFR inhibitor erlotinib....Thirty-two patients with BRAF V600E positive metastatic colorectal cancer(mCRC)...Among 31 evaluable patients with mCRC and 7 with other cancers, overall response rates were 32% (10/31, 16% (5/31) confirmed) and 43% (3/7) respectively; with clinical benefit rates of 65% and 100%.
DOI:
10.1158/1078-0432.CCR-22-3094
Source:
Title:
Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
Excerpt:
Combination of vemurafenib and erlotinib resulted in increased antitumor activity (P < 0.05) and survival (P < 0.0001) compared with monotherapy with either agent (Fig. 6A and B, and Supplementary Table S4).
DOI:
10.1158/0008-5472.CAN-11-2941
